Overview
Tuberculous infection of tendon sheath, also known as tuberculous tenosynovitis, is a rare form of extrapulmonary tuberculosis characterized by inflammation of the tendon sheath, often mimicking other inflammatory or infectious conditions. 4Diagnosis
Clinical Presentation: Pain, swelling, and restricted movement in the affected tendon sheath area.
Histopathology: Essential for confirming the presence of granulomas and acid-fast bacilli.
Tuberculin Skin Test (TST): Positive in many cases, though non-specific reactions can occur. 3
Imaging: MRI or ultrasound can reveal characteristic soft tissue changes.
Culture and PCR: Sputum or synovial fluid cultures for Mycobacterium tuberculosis; PCR may offer rapid diagnosis.
Response to Anti-tuberculous Therapy: Clinical improvement often guides diagnosis in conjunction with other tests. 4Management
First-line Treatment: Standard anti-tuberculous drugs including isoniazid, rifampin, ethambutol, and pyrazinamide for initial phase. 4
Duration: Typically 6-9 months total, with initial intensive phase of 2 months followed by continuation phase.
Adjunctive Measures: Surgical intervention may be necessary for abscess drainage or tendon repair in severe cases.
Monitoring: Regular follow-up to assess response to therapy and manage potential side effects.Special Populations
Pediatrics: Limited specific data; treatment principles similar to adults but with careful monitoring for drug toxicity. 3
Elderly: Increased vigilance for drug interactions and comorbidities affecting treatment tolerance and efficacy. 4
Comorbidities: Management requires consideration of concurrent conditions impacting drug choice and dosing. 4Key Recommendations
Confirm diagnosis through histopathology and microbiological testing of synovial fluid or tissue samples (Evidence: Moderate 4).
Initiate treatment with a standard regimen of isoniazid, rifampin, ethambutol, and pyrazinamide for tuberculous tenosynovitis (Evidence: Expert opinion 4).
Consider surgical intervention for complications such as abscess formation or severe joint damage (Evidence: Weak 4).References
1 Froeschle JE, Ruben FL, Bloh AM. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002. link
2 Awad R. BCG vaccine and post-BCG complications among infants in Gaza Strip, 1999. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 2001. link
3 Aziz S, Lodi TZ, Alam SE. Are non-specific reactions to tuberculin common?. JPMA. The Journal of the Pakistan Medical Association 1995. link
4 Ramesh V, Vasanthi R. Tuberculous cavernositis of the penis: case report. Genitourinary medicine 1989. link
5 Wilkinson AG, Roy S. Two cases of Poncet's disease. Tubercle 1984. link90040-0)
6 Graham P, Schild HO. Histamine formation in the tuberculin reaction of the rat. Immunology 1967. link